ABIOMED, Inc. Presents at UBS Global Healthcare Conference, May-22-2013 10:00 AM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Susie Lisa, Senior Director, Investor Relations.

ABIOMED, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended March 31, 2013. For the quarter, the company reported revenue of $43,674,000 against $37,344,000 a year ago. Income from operations was $4,132,000 against $2,942,000 a year ago. Income before provision for income taxes was $4,140,000 against $2,928,000 a year ago. Net income was $3,742,000 against $2,567,000 a year ago. Diluted net income per share was $0.09 against $0.06 a year ago. Cash generated of $7.6 million from operating activities, used $0.8 million for CapEx. For the year, the company reported revenue of $158,124,000 against $126,375,000 a year ago. Income from operations was $16,543,000 against $1,520,000 a year ago. Income before provision for income taxes was $16,862,000 against $2,543,000 a year ago. Net income was $15,014,000 against $1,495,000 a year ago. Diluted net income per share was $0.37 against $0.04 a year ago. Cash generated of $26.4 million from operating activities, used $2.8 million for CapEx. Based on current expectations, the company expects fiscal year 2014 revenue to be in the range of $180 million to $185 million. Worldwide Impella revenue is forecasted to increase by approximately 20%. GAAP operating margin rate for the full fiscal year is expected to be in the range of 7% to 8% of revenue, including estimated legal costs of approximately $6.0 million to $8.0 million associated with the Department of Justice and shareholder matters.

ABIOMED, Inc. announced the publication of the PROTECT II Cost Effectiveness Study in the American Health & Drug Benefits (AHDB) journal, titled "A Value-Based Analysis of Hemodynamic Support Strategies for High-Risk Heart Failure Patients Undergoing a Percutaneous Coronary Intervention." The study demonstrated a gain in quality of life for Impella patients over the current standard of care, the intra-aortic balloon pump (IABP), at an incremental cost-effectiveness ratio (ICER) of $39,389/QALY (Quality Adjusted Life Year), well below the $100,000/QALY threshold commonly used in the United States or the $50,000/QALY threshold of dialysis. PROTECT II was the first multicenter, randomized trial comparing non-emergent use of hemodynamic support in patients with depressed left ventricular function and complex anatomy that analyzed both the clinical and economic benefits of hemodynamic support. The clinical trial outcomes data and actual billing data from patients were modeled over ten years using a Markov Model to derive the ICER/QALY.